Zura Bio Limited
Zura Bio Limited（ZURA）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · ZURA · 截至 2025年9月30日
股东结构概览
71
机构持有人数
▲ 8 vs Q2
$178.16M
机构持仓总市值
▲ $141.05M vs Q2
65.02M
总流通股
freeFloat 55.59%
41.15M
13F 申报持股数
▲ 5.80M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
ZURA 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
SUVRETTA CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 5.47M | 5.80% | 5.80% | $23.70B | Nov 14, 2025 | ▲ 612.0K |
VR ADVISER, LLC biological products, (no diagnostic substances) | 4.63M | 4.91% | 4.91% | $20.05B | Nov 14, 2025 | — held |
JPMORGAN CHASE & CO biological products, (no diagnostic substances) | 4.62M | 4.90% | 4.90% | $20.02B | Nov 26, 2025 | ▼ 35.8K |
GREAT POINT PARTNERS LLC biological products, (no diagnostic substances) | 3.82M | 4.05% | 4.05% | $16.52B | Nov 14, 2025 | ▲ 645.7K |
ADAGE CAPITAL PARTNERS GP, L.L.C. biological products, (no diagnostic substances) | 3.05M | 3.23% | 3.23% | $13.19B | Nov 14, 2025 | NEW |
PFIZER INC biological products, (no diagnostic substances) | 2.97M | 3.15% | 3.15% | $12.86B | Nov 13, 2025 | — held |
BRAIDWELL LP biological products, (no diagnostic substances) | 2.47M | 2.62% | 2.62% | $10.71B | Nov 14, 2025 | — held |
IKARIAN CAPITAL, LLC biological products, (no diagnostic substances) | 2.13M | 2.26% | 2.26% | $9.23B | Nov 14, 2025 | NEW |
ARMISTICE CAPITAL, LLC biological products, (no diagnostic substances) | 1.56M | 1.65% | 1.65% | $6.75B | Nov 17, 2025 | ▲ 24.0K |
AFFINITY ASSET ADVISORS, LLC biological products, (no diagnostic substances) | 1.27M | 1.35% | 1.35% | $5.52B | Nov 13, 2025 | ▲ 1.05M |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
15
增持
+3.08M 股12
新建仓
首次建仓17
减持
−4.55M 股0
清仓
完全退出净股数变化（前50家）
1.47M
+3.08M / −4.55M
净新增持仓人
+10
新建 12 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
ZURA 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
5
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Whale Gary Chief Technology Officer | Apr 1, 2026 | Award | 263,000 | $6.03 | $1.59M | 263.0K | Form 4 ↗ |
Nistala Kiran See Remarks | Apr 1, 2026 | Award | 340,900 | $6.03 | $2.06M | 340.9K | Form 4 ↗ |
Hyllengren Eric J Chief Financial Officer | Apr 1, 2026 | Award | 340,900 | $6.03 | $2.06M | 340.9K | Form 4 ↗ |
Davis Kim Chief Legal Officer | Apr 1, 2026 | Award | 425,700 | $6.03 | $2.57M | 425.7K | Form 4 ↗ |
Kulkarni Sandeep Chidambar Chief Executive Officer | Apr 1, 2026 | Award | 894,000 | $6.03 | $5.39M | 894.0K | Form 4 ↗ |
Nirula Ajay director | Feb 21, 2026 | Award | 37,812 | $6.53 | $246.9K | 37.8K | Form 4 ↗ |
AI Biotechnology LLC 10 percent owner | Feb 26, 2026 | Purchase | 2,000,000 | $6.25 | $12.50M | 6.55M | Form 4 ↗ |
Eisner Mark director | Feb 21, 2026 | Award | 37,812 | $6.53 | $246.9K | 37.8K | Form 4 ↗ |
Thiara Parvinder director | Jan 23, 2026 | Award | 38,823 | $6.36 | $246.9K | 38.8K | Form 4 ↗ |
Kulkarni Sandeep Chidambar Chief Executive Officer | Jan 21, 2026 | Award | 2,934,107 | $6.32 | $18.54M | 2.93M | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Zura Bio Limited（ZURA）主要由机构投资者持有，机构持股比例约为 63.3%。公司内部人员持股约 44.41%，散户及公众持股约占剩余的 0.00%。
Zura Bio Limited 最大机构股东为 SUVRETTA CAPITAL MANAGEMENT, LLC，截至 September 30, 2025 持有约 5.47 million 股，占总流通股的 5.80%。
目前共有 71 家机构持有 ZURA 股票，合计持仓市值约 $178,160,287，数据来源为最新 SEC 13F 申报。
常见问题
ZURA ownershipZura Bio Limited（ZURA）主要由机构投资者持有，机构持股约 63.3%。最大股东为 SUVRETTA CAPITAL MANAGEMENT, LLC，持股比例 5.80%。内部人员持股约 44.41%。数据来源 SEC Form 13F，截至 September 30, 2025。